Abstract

PurposeOverall survival of malignant brain tumour patients has significantly been increased over the last years. However, therapy remains palliative, and side effects should be balanced. Once terminal phase is entered, both patients and caregivers may find it hard to accept, and further therapies are demanded. But little is known about this highly sensitive period. Therefore, we analysed the last therapy decisions from the family caregiver’s perspective. Would they support their beloved ones in the same way or would they now recommend a different therapy decision?MethodsCaregivers of deceased malignant brain tumour patients, treated at our neurooncological centre between 2011 and 2017, were included. We designed a questionnaire to analyse the impact of the last therapy decision (resection, chemotherapy, radiotherapy), focusing on probable repeat of the choice taken and general therapy satisfaction. Independent variables, for example “satisfaction with therapy”, were analysed using linear regression analysis, the coefficient of determination R2 and the standardized regression coefficient β. The binary logistic regression analyses were taken to illustrate relationships with the dichotomously scaled outcome parameter “re-choice of therapy”. Odds ratio analyses were used to determine the strength of a relationship between two characteristics.ResultsData from 102 caregivers (life partners (70.6%)) were analysed retrospectively. Each 40% of patients died in a hospice or at home (20% in a hospital). In 67.6% the last therapy was chemotherapy followed by radiotherapy (16.7%) and surgery (15.7%). A positive evaluation of the last therapy was significantly correlated to re-choosing of respective therapy (chemo-/radiotherapy: p = 0.000) and satisfaction with informed consent (p = 0.000). Satisfaction regarding interpersonal contact was significantly correlated to satisfaction with resection (p = 0.000) and chemotherapy (p = 0.000 27 caregivers (28.7%) felt overburdened with this situation).ConclusionThis analysis demonstrates a significant correlation between a positive relation of patient/caregiver/physician and the subjective perception of the latest therapy. It underlines the central role of caregivers, who should be involved in therapy discussions. Neurooncologists should be specially trained in communication and psycho-oncology.

Highlights

  • Due to improved and aggressive treatment options, overall survival of malignant glioma patients is significantly increased from 14.6 to 48.1 months [1,2,3,4] during the last decade—therapy still remains palliative

  • Supportive Care in Cancer neurooncologists will transform into best supportive-care treatment, which is usually conducted by general practitioners or palliative healthcare personnel [5], leading over to the end-of-life (EOL) phase

  • We conducted a cross-sectional survey study of caregivers with the following inclusion criteria: caregivers of (1) recurrent malignant brain tumour patients, (2) who were offered a neurooncological treatment at the neurooncological centre of the university hospital of Duesseldorf and (3) died due to recurrent brain tumour between 2011 and 2017

Read more

Summary

Introduction

Due to improved and aggressive treatment options, overall survival of malignant glioma patients is significantly increased from 14.6 to 48.1 months [1,2,3,4] during the last decade—therapy still remains palliative. Initial tumour-specific treatment, which is mainly guided by special. Supportive Care in Cancer neurooncologists will transform into best supportive-care treatment, which is usually conducted by general practitioners or palliative healthcare personnel [5], leading over to the end-of-life (EOL) phase. The EOL phase is defined as time prior to death when symptom load increases and antitumoural therapy is no longer effective. The EOL phase treatment is determined by palliative and/or supportive care. Patients and their caregivers are explicitly seeking for further treatment options mainly because they are not willing to stop active treatment phase [8, 9]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.